Single-dose extended-release oral azithromycin vs. 3-day azithromycin for the treatment of group A β-haemolytic streptococcal pharyngitis/tonsillitis in adults and adolescents: a double-blind, double-dummy study  by Jorgensen, D.M.
Single-dose extended-release oral azithromycin vs. 3-day azithromycin
for the treatment of group A b-haemolytic streptococcal pharyngitis/
tonsillitis in adults and adolescents: a double-blind, double-dummy study
D. M. Jorgensen
Pﬁzer Inc., New London, CT, USA
Abstract
The azithromycin immediate-release formulation (AZ-IR) provides effective treatment for group A b-haemolytic streptococcal pharyngi-
tis in adults. Single-dose therapy with a novel azithromycin extended-release (AZ-ER) formulation could reduce treatment failure and
eliminate non-compliance contributing to antimicrobial resistance. A randomized, double-blind, double-dummy, multicentre trial was
conducted comparing AZ-ER (single oral 2-g dose) with AZ-IR (3 days, 500 mg once daily) for the treatment of group A b-haemolytic
streptococcal pharyngitis/tonsillitis in adults and adolescents (n = 598). The primary endpoint was bacteriological eradication at test -
of-cure (TOC; day 24–28) in the bacteriological per-protocol population (n = 420). Bacteriological eradication was achieved in 85.4%
(175/205) and 81.4% (175/215) of subjects in the AZ-ER and AZ-IR groups, respectively (95% CI )3.1–11.1). Clinical cure at TOC
occurred in 99.0% of subjects in the AZ-ER group and in 96.7% in the AZ-IR group. At long-term follow-up, bacteriological recurrence
was observed in 5.5% (9/163) and 7.7% (12/156), respectively. Both treatments were well tolerated; and most adverse events (AEs)
were mild to moderate in intensity. The most frequent treatment-related AE was diarrhoea, or loose stools, in 11% of both treatment
groups. AZ-ER-treated and AZ-IR-treated subjects had AE burdens (AE days/patient-year) of 7.6 days and 9.2 days, respectively. A sim-
ilar trend in favour of AZ-ER was noted for treatment-related diarrhoea burden (1.9 days vs. 2.5 days). A single 2-g dose of AZ-ER
is as effective and well tolerated as 3 days of AZ-IR (500 mg once daily) for treating group A b-haemolytic streptococcal pharyngitis/
tonsillitis in adults and adolescents.
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Introduction
Antibiotic treatment is recommended for group A b-haemo-
lytic streptococcal pharyngitis to prevent rheumatic fever,
hasten symptom resolution, limit transmission, and prevent
suppurative complications [1].
Several studies have documented the efﬁcacy of the azi-
thromycin immediate-release formulation (AZ-IR) when given
for 3 days (500 mg once daily) to adults with streptococcal
pharyngitis/tonsillitis [2–4], and this 3-day treatment has been
approved in many countries. In children, a 3-day course of
azithromycin totalling 60 mg/kg has proved more effective
than 30 mg/kg, and bacteriological failure was ﬁve-fold lower
in patients receiving 60 mg/kg over 3 days than in those trea-
ted with 10-day courses of comparators [5].
A novel microsphere-based azithromycin extended-release
formulation (AZ-ER) allows administration of a higher oral
dose of azithromycin as a single-dose regimen, while main-
taining tolerability [6]. Drug exposure after a single 2-g oral
dose of AZ-ER is considerably higher than that achieved with
a 1.5-g total dose of AZ-IR administered over 3 or 5 days.
This so-called ‘front-loading’ of the dose early during the
course of infection maximizes drug exposure when the bac-
terial burden is highest. Front-loading increases the AUC0–24/
MIC ratio, the parameter that best predicts azithromycin
efﬁcacy [7]. Data from animal infection models suggest that
this approach is effective in a variety of infections [8] (Kam-
icker et al., 44th ICACC, 2004, Abstract 1181B). In addition,
clinical trials have demonstrated that AZ-ER is as effective
and well tolerated as comparator antibiotics in the treatment
of community-acquired pneumonia, acute exacerbations of
chronic bronchitis, and acute bacterial rhinosinusitis [9–12].
ª2009 Pﬁzer, Inc.
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE 10.1111/j.1469-0691.2009.02718.x
Therefore, this study was performed to conﬁrm whether a
single 2-g oral dose of AZ-ER is bacteriologically non-inferior
to a 500-mg once-daily dose for 3 days of AZ-IR when used
to treat adults and adolescents with group A b-haemolytic
streptococcal pharyngitis/tonsillitis.
Materials and Methods
Study design and ethics
This was a phase 3, multicentre, randomized, double-blind,
double-dummy study comparing the efﬁcacy and safety of a
single 2-g oral dose of AZ-ER with a 500 mg once-daily dose
for 3 days of AZ-IR for the treatment of acute group A
b-haemolytic streptococcal pharyngitis/tonsillitis in adults and
adolescents (NCT00644293, http://www.clinicaltrials.gov).
The study was conducted in accordance with the Interna-
tional Conference on Harmonization Guidelines for Good
Clinical Practice, the Declaration of Helsinki, and the US
Food and Drug Administration regulations for informed con-
sent and protection of patient rights. The protocol, consent
documents and all protocol amendments were approved by
each participating centre’s Institutional Review Board and the
appropriate Ethics Committee. Written informed consent
was required prior to study enrolment.
Subjects
Key inclusion criteria. The patients included were male or
female outpatients, aged ‡13 years, with erythematous pharyn-
geal mucosa or thick exudate covering the pharynx and tonsil-
lar area and at least one of the following signs or symptoms of
acute pharyngitis/tonsillitis: sore/scratchy throat, pain on swal-
lowing, chills and/or fever, cervical adenopathy, scarlet fever
rash on the face and skin folds, or red tongue with prominent
papillae. Either a positive rapid antigen detection test (subse-
quently to be conﬁrmed by culture) or a group A b-haemolytic
streptococcus (GABHS)-positive culture of pharyngeal or ton-
sillar specimens was also required for subjects to be included.
Key exclusion criteria. Subjects were excluded if they had
received treatment with any systemic antibiotic within the
previous 7 days, were known carriers of GABHS (e.g. with a
past history of GABHS-positive cultures but without clinical
signs or symptoms of acute group A b-haemolytic strepto-
coccal pharyngitis/tonsillitis), had a history of rheumatic
fever, or had a peritonsillar abscess.
Treatment
Allocation to treatment with AZ-ER or AZ-IR was double-
blind. AZ-ER and matching placebo were supplied as 2 g of
powder for oral suspension, to be taken as a single directly
observed dose on day 1. AZ-IR (500-mg tablets) and match-
ing placebo were taken once daily for 3 days. The ﬁrst dose
was given as directly observed therapy on day 1. Patients
were randomized in a 1 : 1 ratio to treatment using a com-
puter-generated code at a central randomization centre con-
tacted by telephone. A method of permutated blocks (block
size of four), balanced within a site, was used.
Assessment
The primary efﬁcacy endpoint was the bacteriological
response to the AZ-ER and AZ-IR regimens at the test-
of-cure (TOC) visit (day 24–28) in the bacteriological per-
protocol (BPP) population. This population was deﬁned as
having a GABHS-positive culture at baseline or within 48 h
of study therapy, having received at least two-thirds of study
drug, having received no concomitant systemic antibiotic
with activity against GABHS, and being assessed in the
appropriate visit window.
The following criteria were used to determine bacterio-
logical response: for eradication, absence of GABHS from
the culture of a pharyngeal specimen obtained at TOC and
no additional antibiotic active against GABHS given for treat-
ment failure; for persistence, continued presence of GABHS
in the culture of a pharyngeal specimen obtained at TOC
assessment.
Secondary efﬁcacy assessments included sponsor-classiﬁed
clinical outcome (collected for the BPP population only) at
TOC and long-term follow-up (LTFU; day 38–45) visits and
bacteriological eradication at TOC by susceptibility of
baseline isolate to azithromycin. Clinical outcome was classi-
ﬁed as cure if no additional antibiotics were necessary, if at
least one of the cardinal signs or symptoms had improved or
resolved, if the remaining cardinal signs or symptoms had
improved or remained the same, and if no new cardinal sign
or symptom had appeared. Continued bacteriological eradi-
cation (and bacteriological recurrence) at LTFU in the BPP
population was based on BPP subjects with a negative culture
at TOC returning for a follow-up culture at LTFU. Contin-
ued clinical cure (and clinical relapse) at LTFU in the BPP
population was based on BPP subjects with an assessment of
clinical cure at TOC who returned for a follow-up clinical
assessment at LTFU.
Susceptibility was determined using broth microdilution
and established NCCLS breakpoints for azithromycin; non-
susceptibility was deﬁned as an MIC >0.5 mg/L. Pulsed-
ﬁeld gel electrophoresis (PFGE) was carried out with all
available paired isolates (baseline vs. TOC) to distinguish
between true bacteriological failure and a newly acquired
infection.
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Treatment compliance
The investigator directly observed compliance concerning
the ﬁrst dose of study medication. Subjects were questioned
during the end-of-therapy (day 4–6) ofﬁce visit, or at the
corresponding time by telephone, to assess compliance with
subsequent dosing. In addition, subjects were asked to bring
their unused study medication to the TOC visit.
Safety
All treated subjects were evaluable for safety. Adverse
events (AEs) were recorded for all treated subjects during
clinic visits. These AEs were evaluated by the investigator for
intensity (mild—transient and requiring no special treatment
or intervention; moderate—impacting on usual daily activities
and alleviated by simple therapeutic treatments;
severe—interrupting usual daily activities and requiring thera-
peutic intervention) and their relationship to the study drug
(treatment-related or related to any other cause).
Any AE for which no such relationship could be estab-
lished was classiﬁed as treatment-related by default; all sum-
maries reported in the results include only treatment-related
AEs up to 35 days following the end of study treatment. In
addition to determining the frequency of treatment-related
AEs, the treatment-related AE burden (AE days/patient-
year) was calculated for treatment-related AEs.
Statistical methods
The sample size of the BPP population required to demon-
strate at least non-inferiority of AZ-ER to AZ-IR was deter-
mined to be 402 subjects, based on the following
assumptions: (i) 80% power to show non-inferiority based
on a two-sided 95% CI (constructed using a normal approxi-
mation to the binomial distribution without adjustment for
centres); (ii) a non-inferiority criterion requiring the lower
boundary of the 95% CI around the difference in eradication
rates (AZ-ER minus AZ-IR) to be >)10%; and (iii) an
assumed eradication rate of 85% in both treatment groups.
To account for an estimated 20% non-evaluability rate, a
total of 504 subjects was targeted for enrolment. Because
the actual evaluability rate was lower than initially expected,
598 subjects were enrolled, resulting in 420 subjects in the
TOC BPP population. All other analyses were descriptive.
Results
Demographics
The study was performed between April 2003 and 2004. Of
the 598 subjects randomized, 345 were enrolled in the USA
(from seven community-based clinical research centres and
three general practitioner (GP) practices), 71 in France (from
six GP practices), 59 in the UK (from eight GP practices), 41
in Germany (from eight GP practices), 35 in India (from four
hospital outpatient clinics), 22 in Italy (from six GP prac-
tices), and the remainder in Belgium, Finland, The Nether-
lands, and Norway (from two hospital outpatient clinics and
eight GP practices). Five hundred and ninety-four subjects
(99%) were treated with either AZ-ER or AZ-IR for 3 days.
Of the 594 treated subjects, 543 (91%) completed the study.
Demographic characteristics were similar across treat-
ment groups (Table 1). Approximately 38% of subjects were
male and 62% were female. The mean ages of subjects were
30.3 years (range: 13–67 years) in the AZ-ER arm and
30.0 years (range: 13–73 years) in the AZ-IR arm.
Bacteriological efﬁcacy
Two hundred and ﬁve of 296 (69.3%) AZ-ER-treated sub-
jects and 215 of 298 (72.1%) AZ-IR-treated subjects were
included in the BPP population at TOC (Fig. 1). The TOC
bacteriological eradication rate was 85.4% (175/205) for AZ-
ER-treated subjects and 81.4% (175/215) for AZ-IR-treated
subjects (Fig. 2a), with a 95% CI for the difference in eradica-
tion rates of )3.1–11.1. Eradication rates were 76.6% in Eur-
ope and 86.7% in the USA; GABHS was eradicated in all 11
cases from India. Incidences of resistant GABHS in Europe
and the USA were 18.0% and 4.1%, respectively. Incidences
of resistant GAHBS varied within Europe (Table 2), and
TABLE 1. Demographics (all treated patients)
AZ-ER
(2-g single
oral dose)
(n = 296)
AZ-IR
(500 mg once daily,
3 days)
(n = 298)
Males/females, n 108/188 115/183
Age (years)
Mean (SD) 30.3 (10.5) 30.0 (11.1)
Range 13–67 13–73
Ethnicity, n (%)
White 265 (89.5) 261 (87.5)
Black 6 (2.0) 6 (2.0)
Asian 18 (6.1) 20 (6.7)
Hispanic 5 (1.7) 8 (2.7)
Other 2 (0.7) 3 (1.0)
Weight (kg)
Mean (SD) 73.1 (20.8) 74.4 (20.9)
Range 32.0–151.0 30.0–172.0
n 290 294
Height (cm)
Mean (SD) 169.1 (10.3) 169.4 (11.1)
Range 139.0–196.0 138.0–201.0
n 290 295
Previous respiratory
infection, n (%)
38 (12.8) 44 (14.8)
Previous
pharyngitis/tonsillitis, n (%)
27 (9.1) 32 (10.7)
Previous antibiotics, n (%)a 4 (1.3) 4 (1.4)
AZ-ER, azithromycin extended-release formulation; AZ-IR, azithromycin immedi-
ate-release formulation; SD, standard deviation.
aAntibacterial treatment within 30 days prior to start of study treatment.
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were highest in Italy (58.8%), Finland (50%), and France
(26.5%).
PFGE analysis was performed for all but six persistent iso-
lates at TOC to determine whether they represented newly
acquired infections rather than true bacteriological failures.
The results indicated that only two patients, both in the AZ-ER
group, had new infections rather than infections due to
persistent strains. The adjusted bacteriological eradication
rates, accounting for the PFGE data, were 86.3% (177/205)
for the AZ-ER group and 81.4% (175/215) for the AZ-IR
group (95% CI )2.1–12.0). There was no evidence of emer-
gence of resistance in persistent strains in either arm of the
study.
For the susceptible isolates, the eradication rate in the
AZ-ER arm was 90.4% (170/188), as compared with 85.3%
(168/197) in the AZ-IR arm. For the azithromycin-non-sus-
ceptible isolates, which accounted for 7.5% (33/440) of the
GABHS isolates, the eradication rate in the AZ-ER arm was
31.3% (5/16), as compared with 35.3% (6/17) in the AZ-IR
arm. The bacteriological recurrence rate at LTFU was 5.5%
FIG. 1. CONSORT ﬂow diagram for the double-blind, double-dummy study evaluating the azithromycin extended-release formulation (AZ-ER)
vs. the immediate-release formulation (AZ-IR). TOC, test-of-cure; BPP, bacteriological per-protocol population; LTFU, long-term follow-up;
GABHS, group A b-haemolytic streptococcus.
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(9/163) in the AZ-ER arm, as compared with 7.7% (12/156)
in the AZ-IR arm, among the BPP subjects with documented
eradication at TOC (Fig. 2a).
Clinical efﬁcacy
The clinical cure rates at TOC for the BPP subjects were
99.0% (203/205) and 96.7% (208/215) when treated with
AZ-ER and AZ-IR, respectively (95% CI )1.7–8.3; Fig. 2b).
The continued clinical cure rates at LTFU were 92.1%
(176/191) and 95.2% (178/187) for subjects in the AZ-ER
and AZ-IR treatment groups, respectively (Fig. 2b).
Compliance
One hundred per cent of subjects in the AZ-ER group and
98% in the AZ-IR group complied with active treatment.
Safety
Subjects experienced treatment-related AEs at similar rates
in the AZ-ER group (20.3%; 60/296) and in the AZ-IR group
(19.5%; 58/298). The majority of treatment-related AEs were
of mild or moderate severity. No treatment-related serious
AEs were reported, and no subjects discontinued the study
because of treatment-related AEs. The most common treat-
ment-related AE was diarrhoea or loose stools, which
occurred in c. 11% of the AZ-ER-treated subjects (31/296)
and the AZ-IR-treated subjects (32/298) (Table 3).
Subjects in the AZ-ER arm had a treatment-related AE
burden of 7.6 days/patient-year, vs. 9.2 days in the AZ-IR
arm. A similar trend in favour of AZ-ER was noted for the
treatment-related diarrhoea burden (1.9 days vs. 2.5 days/
patient-year; Table 3).
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FIG. 2. Rates of (a) bacteriological eradication and (b) clinical cure
at test-of-cure (TOC) and continued at long-term follow-up (LTFU)
in those subjects with eradication at the TOC visit and cured at the
TOC visit, respectively (bacteriological per-protocol population).
AZ-ER, azithromycin extended-release formulation; AZ-IR, azithro-
mycin immediate-release formulation. [For the LTFU analyses, evalu-
able subjects in the bacteriologic per-protocol population also had
to be classiﬁed as having bacteriological eradication at the TOC visit.
Similarly, in Figure 2b, the LTFU evaluable subjects in the bacteriolo-
gical per-protocol population also had to be classiﬁed as having a
clinical cure at the TOC visit.]
TABLE 2. Baseline group A b-haemolytic streptococcus
(GABHS) susceptibility to azithromycin by country in all
randomized subjects
Country
Total no.
of GABHS
isolates
Susceptibility
Susceptible Intermediate Resistant
All 490 442 2 46
Belgium 6 5 0 1
Finland 4 2 0 2
France 64 46 1 17
Germany 34 31 1 2
India 11 10 0 1
Italy 17 7 0 10
The Netherlands 2 2 0 0
Norway 6 6 0 0
UK 50 49 0 1
USA 296 284 0 12
TABLE 3. Treatment-related adverse events (AEs)a and
treatment-related adverse event burden in all treated
patients
AZ-ER
(2-g single
oral dose)
(n = 296)
AZ-IR
(500 mg once
daily, 3 days)
(n = 298)
Treatment-related adverse events (no. (%) of patients)
Diarrhoea/loose stools 31 (10.5) 32 (10.7)
Nausea 13 (4.4) 4 (1.3)
Abdominal pain 9 (3.0) 14 (4.7)
Headache 6 (2.0) 1 (0.3)
Treatment-related adverse event burden
Total observation days 12 372 12 414
Overall AE burden
(days/patient-year)
7.6 9.2
Gastrointestinal AE burden
(days/patient-year)
Diarrhoea 1.9 2.5
Vomiting 0.2 0.1
Abdominal pain 0.5 0.9
Nausea 0.7 0.2
AZ-ER, azithromycin extended-release formulation; AZ-IR azithromycin immedi-
ate-release formulation.
aIncludes adverse events occurring in ‡2% of subjects in either treatment group.
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Discussion
Penicillin V has been considered the drug of choice for the
treatment of group A b-haemolytic streptococcal pharyngitis
because of its proven ability to prevent acute rheumatic
fever [13,14]. However, there have been concerns about the
increasing rate of treatment failures with b-lactam antibiotics.
For example, bacteriological failures have been observed in
up to 35% of GABHS patients treated with penicillin V [15].
Furthermore, a recent meta-analysis of nine randomized con-
trolled trials (involving 2113 patients) comparing cephalospo-
rins with penicillin demonstrated that the likelihood of
bacteriological and clinical failure in the treatment of
group A b-haemolytic streptococcal tonsillopharyngitis is
two-fold higher with oral penicillin than with oral cephalo-
sporins [16].
A number of studies have demonstrated that macrolides
and cephalosporins offer efﬁcacy and safety equivalent to
penicillin, and a more convenient dosing regimen [17–19].
These ﬁndings are reﬂected in recent guidelines of the
American Academy of Family Physicians for the treatment of
upper respiratory tract infections in adults and children [20].
This report listed penicillin V or benzathine penicillin G as
ﬁrst-choice therapy, and macrolides, cephalosporins or clin-
damycin as alternatives, for adults with group A b-haemolytic
streptococcal pharyngitis. In particular, macrolides were rec-
ommended as an alternative for patients allergic to penicillin.
Other national guidelines may differ according to the preva-
lence of resistance.
There has been recent concern about the emergence of
macrolide resistance in GABHS, although levels appear to
remain stable [21,22]. The increase in resistance has been
linked to changing patterns in macrolide prescribing, which
was ﬁrst observed in Finland [23], and has also been
reported in Italy [24] and France [25]. It has been sug-
gested that macrolide resistance may be the result of un-
derdosing macrolides for the treatment of group A b-
haemolytic streptococcal pharyngitis/tonsillitis [25].There is
evidence, however, that individual GABHS clones, which
may be antibiotic-resistant, may become dominant in a par-
ticular community before being replaced by another clone;
this process was already evident before the extensive use
of macrolides [26].
A meta-analysis of paediatric trials of azithromycin has
demonstrated that higher doses (60 mg/kg vs. 30 mg/kg total)
and shorter courses of azithromycin treatment (3 days vs.
5 days of AZ-IR) are associated with better outcomes in
group A b-haemolytic streptococcal pharyngitis [5]. There-
fore, the aim of this study was to compare the existing 3-day
AZ-IR formulation with a novel single-dose AZ-ER formula-
tion for the treatment of group A b-haemolytic streptococcal
pharyngitis/tonsillitis. As GABHS is the cause of acute pharyn-
gitis in only 5–10% of adults [14], the aetiology of the
infection was conﬁrmed bacteriologically. The BPP eradication
rate was selected as the primary measure of efﬁcacy, consis-
tent with FDA regulatory guidance for evaluating new treat-
ments for group A b-haemolytic streptococcal pharyngitis/
tonsillitis.
BPP eradication rates were similar for subjects treated
with AZ-ER and AZ-IR. On the basis of the 95% CI for the
difference in these rates, a single dose of AZ-ER was found
to be as effective as the 3-day regimen of AZ-IR in the
treatment of acute group A b-haemolytic streptococcal
pharyngitis/tonsilitis. Moreover, the AZ-ER bacteriological
eradication rate observed at TOC (85%) was similar to rates
reported for both penicillin and comparator antibiotics in
other adult group A b-haemolytic streptococcal pharyngitis
trials [17–19]. Reduced susceptibility of isolates to azithro-
mycin did not appear to be a major concern, with only 7.5%
being identiﬁed as non-susceptible. However, rates of eradi-
cation of non-susceptible strains were reduced with both
AZ-ER and AZ-IR.
In countries with higher incidences of macrolide resis-
tance, eradication rates tended to be lower, which reinforces
the importance of monitoring macrolide susceptibility on a
geographical basis. More importantly, there was no evidence
of the emergence of resistance among GABHS isolates
recovered after treatment, which may be an advantage of
higher, front-loaded doses [27]. Bacteriological recurrence
rates were low in both treatment groups (5.5% in the AZ-
ER group and 7.7% in the AZ-IR group at LTFU) and similar
to those observed in other GABHS trials [17–19]. There-
fore, this trial demonstrates that AZ-ER has bacteriological
efﬁcacy that is equivalent to that of AZ-IR, and comparable
to that of penicillin V and other antibiotics.
Clinical cure rates in the BPP population were above 96%
at TOC, and the continued clinical cure rates remained
above 92% at LTFU for both treatment groups. Like bacteri-
ological eradication rates, the clinical cure rates with AZ-ER
and AZ-IR observed in this study were comparable to those
reported in recent clinical group A b-haemolytic streptococ-
cal pharyngitis trials in adults [17–19].
The overall incidence of treatment-related AEs was similar
in the AZ-ER and AZ-IR groups. This demonstrates that the
entire azithromycin regimen can be administered as a single
2-g dose of microspheres, without increasing the rate of
AEs, particularly gastrointestinal AEs. In addition, the AZ-ER
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group experienced a lower treatment-related AE burden
(days/patient-year), especially of diarrhoea.
Poor compliance with antibiotic treatment regimens not
only results in persistence of pathogens, but also facilitates
the emergence of resistance. For instance, in two studies
of paediatric subjects with acute respiratory tract infec-
tions, comparing different amoxycillin regimens [28,29], the
most important factor associated with treatment failure
was treatment non-compliance. Shorter regimens with con-
venient once-daily dosing are associated with good patient
compliance [30], and in this study, a single dose of AZ-ER
ensured 100% subject compliance. An effective single-dose
regimen has the potential to reduce treatment failure
and to minimize one of the causes of antimicrobial
resistance.
In conclusion, a single 2-g oral dose of AZ-ER is as effec-
tive as a 3-day regimen of AZ-IR (500 mg once daily for
3 days) when used for the treatment of adolescents and
adults with acute group A b-haemolytic streptococcal phar-
yngitis/tonsillitis. Moreover, the AZ-ER formulation allowed
for the ‘front-loading’ of the entire dose without increasing
the rate of AEs. Indeed, the AZ-ER group showed a reduced
AE burden, particularly of treatment-related diarrhoea. In
addition, single-dose therapy maximizes patient compliance,
potentially reducing the development of antimicrobial resis-
tance in the community.
Acknowledgements
Parts of the data were presented at the 15th Annual Euro-
pean Congress of Clinical Microbiology and Infectious Dis-
eases 2005. The author would like to thank S. Kegel,
J. Breen and C. McCoig for their contributions to this study.
Transparency Declaration
This study was sponsored by Pﬁzer Inc. Editorial support
was provided by D. Wolf at PAREXEL and was funded by
Pﬁzer Inc. D. Jorgensen is an employee of Pﬁzer Inc.
References
1. Gwaltney JM, Bisna AL. Pharyngitis. In: Mandell GL, Bennett JE, Dolin
R, eds. Principles and practice of infectious diseases, 5th edn. Philadel-
phia, PA: Churchill Livingstone, 2000; 656–662.
2. Mu¨ller O. An open comparative study of azithromycin and roxithro-
mycin in the treatment of acute upper respiratory tract infections.
J Antimicrob Chemother 1996; 37 (suppl C); 83–92.
3. Mu¨ller O. Comparison of azithromycin versus clarithromycin in the
treatment of patients with upper respiratory tract infections. J Anti-
microb Chemother 1993; 31 (suppl E); 137–146.
4. O’Doherty B. An open comparative study of azithromycin versus
cefaclor in the treatment of patients with upper respiratory tract
infections. J Antimicrob Chemother 1996; 37 (suppl C); 71–81.
5. Casey JR, Pichichero ME. Higher dosages of azithromycin are more
effective in treatment of group A streptococcal tonsillopharyngitis.
Clin Infect Dis 2005; 40: 1748–1755.
6. Blasi F, Aliberti S, Tarsia P. Clinical applications of azithromycin micro-
spheres in respiratory tract infections. Int J Nanomedicine 2007; 2:
551–559.
7. Craig WA. Postantibiotic effects and the dosing of macrolides,
azalides and streptogramins. In: Zinner SH, Young LS, Acar JF, Neu
HC, eds. Expanding indications of the new macrolides, azalides and strep-
togramins. New York: Marcel Dekker, 1997: 22–38.
8. Girard D, Finegan SM, Dunne MW, Lame ME. Enhanced efﬁcacy of
single-dose versus multi-dose azithromycin regimens in preclinical
infection models. J Antimicrob Chemother 2005; 56: 365–371.
9. D’Ignazio J, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel,
single-dose microsphere formulation of azithromycin versus 7-day
levoﬂoxacin therapy for treatment of mild to moderate community-
acquired pneumonia in adults. Antimicrob Agents Chemother 2005; 49:
4035–4041.
10. Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Single-dose azithro-
mycin microspheres vs clarithromycin extended release for the treat-
ment of mild-to-moderate community-acquired pneumonia in adults.
Chest 2005; 128: 2230–2237.
11. Zervos M, Breen JD, Jorgensen DM, Goodrich JM. Novel, single-dose
microsphere formulation of azithromycin versus levoﬂoxacin for the
treatment of acute exacerbation of chronic bronchitis. Infect Dis Clin
Pract 2005; 13: 115–121.
12. Murray JJ, Emparanza P, Lesinskas E, Tawadrous M, Breen JD. Efﬁcacy
and safety of a novel, single-dose azithromycin microsphere formula-
tion versus 10 days of levoﬂoxacin for the treatment of acute
bacterial sinusitis in adults. Otolaryngol Head Neck Surg 2005; 133:
194–200.
13. Pichichero ME, Cohen R. Empiric antibiotic selection criteria for
respiratory infections in pediatric practice. Pediatr Infect Dis J 1997;
16: 680–695.
14. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH.
Practice guidelines for the diagnosis and management of group A
streptococcal pharyngitis. Infectious Diseases Society of America. Clin
Infect Dis 2002; 35: 113–125.
15. Kaplan EL, Johnson DR. Unexplained reduced microbiological efﬁcacy
of intramuscular benzathine penicillin G and of oral penicillin V in
eradication of group A streptococci from children with acute pharyn-
gitis. Pediatrics 2001; 108: 1180–1186.
16. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus peni-
cillin for treatment of group A streptococcal tonsillopharyngitis in
adults. Clin Infect Dis 2004; 38: 1526–1534.
17. Brook I. A pooled comparison of cefdinir and penicillin in the treat-
ment of group A beta-hemolytic streptococcal pharyngotonsillitis. Clin
Ther 2005; 27: 1266–1273.
18. Takker U, Dzyublyk O, Busman T, Notario G. Comparison of 5 days
of extended-release clarithromycin versus 10 days of penicillin V for
the treatment of streptococcal pharyngitis/tonsillitis: results of a mul-
ticenter, double-blind, randomized study in adolescent and adult
patients. Curr Med Res Opin 2003; 19: 421–429.
19. Portier H, Filipecki J, Weber P, Goldfarb G, Lethuaire D, Chauvin
JP. Five day clarithromycin modiﬁed release versus 10 day penicil-
lin V for group A streptococcal pharyngitis: a multi-centre,
open-label, randomized study. J Antimicrob Chemother 2002; 49:
337–344.
CMI D. M. Jorgensen Single-dose vs. 3-day azithromycin in pharyngitis 1109
ª2009 Pﬁzer, Inc.
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1103–1110
20. Wong DM, Blumberg DA, Lowe LG. Guidelines for the use of antibi-
otics in acute upper respiratory tract infections. Am Fam Physician
2006; 74: 956–966.
21. Kaplan E, Johnson D, Del Rosario M, Horn D. Susceptibility of
group A beta-hemolytic streptococci to thirteen antibiotics: examina-
tion of 301 strains isolated in the United States between 1994 and
1997. Pediatr Infect Dis J 1999; 18: 1069–1072.
22. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant
group A streptococci in schoolchildren in Pittsburgh. N Engl J Med
2002; 346: 1200–1206.
23. Seppa¨la¨ H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in
the consumption of macrolide antibiotics on erythromycin resistance
in group A streptococci in Finland. N Engl J Med 1997; 337: 441–446.
24. Gagliotti C, Nobilio L, Milandri M, Moro ML. Emilia-Romagna Antibiotic
Resistance Study Group. Macrolide prescriptions and erythromycin
resistance of Streptococcus pyogenes. Clin Infect Dis 2006; 42: 1153–1156.
25. Bingen E, Bidet P, Mihaila-Amrouche L et al. Emergence of macrolide-
resistant Streptococcus pyogenes strains in French children. Antimicrob
Agents Chemother 2004; 48: 3559–3562.
26. Cleary P, Kaplan E, Handley J, Schlievert P. Clonal basis for resur-
gence of serious Streptococcus pyogenes disease in the 1980s. Lancet
1992; 339: 518–521.
27. Urba´nek K, Kola´r M, Cekanova´ L. Utilization of macrolides and the
development of Streptococcus pyogenes resistance to erythromycin.
Pharm World Sci 2005; 27: 104–107.
28. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT)
pneumonia study group. Clinical efﬁcacy of 3 days versus 5 days of
oral amoxicillin for treatment of childhood pneumonia: a multicentre
double-blind trial. Lancet 2002; 360: 835–841.
29. Agarwal G, Awasthi S, Kabra SK et al. Three day versus ﬁve day
treatment with amoxicillin for non-severe pneumonia in young chil-
dren: a multicentre randomised controlled trial. BMJ 2004; doi:
10.1136/bmj.38049.490255.DE. [Epub ahead of print].
30. Kardas P. Patient compliance with antibiotic treatment for respira-
tory tract infections. J Antimicrob Chemother 2002; 49: 897–903.
1110 Clinical Microbiology and Infection, Volume 15 Number 12, December 2009 CMI
ª2009 Pﬁzer, Inc.
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1103–1110
